Related Experiment Videos
[Amyloidosis in patients with rheumatoid arthritis]
Abstract:
Of 467 patients followed-up for 15 yrs, rheumatoid arthritis was complicated by amyloidosis in 47 (10%). The relationship of amyloidosis development with a high or constantly moderate activity and expression of rheumatoid arthritis and its severity was brought to light. The results of biopsies of the mucosa, kidneys and liver, autopsy and clinical findings were analyzed and correlated. An increase in the frequency of amyloidosis development was noted in patients treated with glucocorticoids whereas in patients receiving cytostatics there was not such an increase.
Insights
Rheumatoid arthritis (RA) can lead to amyloidosis in 10% of patients over 15 years. Glucocorticoid treatment may increase amyloidosis risk, while cytostatics did not show this association.
Area of Science:
- Rheumatology
- Nephrology
- Pathology
Context:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting joints and potentially other organs.
- Amyloidosis, a complication of chronic inflammation, involves protein deposition in tissues.
- Long-term outcomes and complications of RA require ongoing investigation.
Purpose:
- To investigate the incidence and risk factors for amyloidosis in a cohort of rheumatoid arthritis patients over 15 years.
- To correlate amyloidosis development with rheumatoid arthritis activity, severity, and treatment modalities.
- To analyze clinical, biopsy, and autopsy findings for a comprehensive understanding of RA-associated amyloidosis.
Summary:
- Over 15 years, 10% (47/467) of rheumatoid arthritis patients developed amyloidosis.
- Amyloidosis risk was associated with high or moderate rheumatoid arthritis activity and disease severity.
- Glucocorticoid use correlated with increased amyloidosis frequency, whereas cytostatic use did not show a similar association.
Impact:
- Highlights the significant risk of amyloidosis in long-term rheumatoid arthritis management.
- Suggests a potential link between glucocorticoid therapy and increased amyloidosis incidence in RA patients.
- Informs clinical practice regarding monitoring and potential treatment adjustments for RA patients at risk of amyloidosis.